Coping Strategies For China Industry Amid BIOSECURE Overhang

With the US BIOSECURE Act waiting for a Senate vote, there are signs it may be prompting some Chinese firms to look at their operations. In the meantime, two legal experts in China suggest a range of coping strategies for companies that may be deemed "of concern."

forward
Directions for China biotech industry moving forward upon the BIOSECURE Act. • Source: Shutterstock
Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from China

More from Asia